Some highlights of the year include:

- The LRF is proud to have awarded $1,266,000 in research grants to 13 New Investigators around the world (see sidebar). The LRF exclusively funds New Investigators allowing these innovative scientists to act on their ideas and try new procedures and experiments that can lead to significant breakthroughs.

- Nearly $200,000 was disbursed to patients in need to assist in paying their medical bills and medications, allowing them to focus on their treatment and care.

- The annual Town Hall Meeting was held in-person in January, 2020 attracting more than 230 registrants (a record number). Positive feedback from attendees indicated that 70% learned something they didn’t know about their disease and/or treatment and 99% would recommend the program to others.

- The LRF launched our branded Online Support Community in April. The Community, with over 4,000 members across four disease-specific groups, is where Community members gain support from other patients and caregivers living with the same diagnosis at a time when patients are at home and isolated.

- In May, Dr. Jayesh Mehta of the Northwestern University Feinberg School of Medicine answered questions virtually about treatment of hematologic malignancies, stem cell transplantation, and infection prevention precautions in immunocompromised patients (including COVID-19). More than 100 participated from 12 different states.

- The Multiple Myeloma Rounds series successfully completed its fifth year providing a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their multiple myeloma patients. Sessions this year took place in Atlanta, Chicago, Florida, NYC/New Jersey, and Seattle.

- Fundraising totals for the fiscal year eclipsed $2.6 million marking the second highest total in organization history and reflecting a 10% increase over the previous year.

Cancer is costly; physically, emotionally and financially. COVID-19 has made the pivotal role that research plays in addressing threats to our nation, our communities, and our families highly visible.

The LRF includes 21 volunteer chapters comprised of people who have lost a loved one or have been touched by the disease. Their remarkable support and dedication ensures that the LRF will continue to pursue the ultimate cures for all blood-related cancers – as we have since 1946.

We appreciate your support of our mission and all those we serve. Thank you!

Blake Brandwein
Board President

Kevin Radelet
Executive Director

2020 New Investigator Research Grants

Jeevisha Bajaj, Ph.D.
Rochester University, New York
Role of SLC6A6 in aggressive Myeloid Leukemia

Triona Ni Chonghaile, Ph.D., BSc
Royal College of Surgeons, Ireland
Identifying and epigenetically inducing BCL-2 dependence in Multiple Myeloma

Sergi Cuartero, Ph.D.
Josep Carreras Leukaemia Research Institute, Spain
Identifying novel transcriptional vulnerabilities in MDS with cohesin mutations

Heiko Konig, M.D., Ph.D.
Indiana University
A novel approach to target drug resistant Acute Myeloid Leukemia cells

Bridget Marcellino, M.D., Ph.D.
Icahn School of Medicine at Mt. Sinai, New York
Enhancing natural killer cell recognition of leukemic cells

Fabiana Perna, M.D., Ph.D.
Indiana University
Interrogation of the Leukemia cell Surfaceome for immune-targeting

Yana Pikman, M.D.
Dana-Farber Cancer Institute, Massachusetts
Novel combination strategy for targeting one-carbon folate metabolism for T-cell Acute Lymphoblastic Leukemia therapy

Giovanni Roti, M.D., Ph.D.
University of Parma, Italy
Targeting NOTCH1 trafficking vulnerabilities in T-Cell Acute Lymphoblastic Leukemia

Simone Sidoli, Ph.D.
Albert Einstein College of Medicine, New York
Accessible heterochromatin as new target against Acute Myeloid Leukemia development

George Souroullas, Ph.D.
Washington University, Missouri
Understanding the oncogenic mechanisms and chromatin interactions of EZH2 mutations in Lymphoma

Liling Wan, Ph.D.
University of Pennsylvania Perelman School of Medicine
Targeting the chromatin reader protein ENL in acute leukemias

Siao-Yi Wang, M.D., Ph.D.
Loyola University Cardinal Bernardin Cancer Center, Illinois
Engineering CD19-specific chimeric antigen receptor T-cells without inducing cell division or differentiation

Yibin Yang, Ph.D.
Research Institute of Fox Chase Cancer Center, Pennsylvania
Investigating and therapeutic targeting of the IL1R1-MyD88 pathway in Anaplastic Large Cell Lymphoma
The ABC 7 Gibbons 5K Run and 3K Walk was held virtually for the first time, giving participants a safe alternative to support our cause.

Miri Mera, M.D. Ph.D. of The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York, was selected to the National Academy of Sciences in 2020. Her research was funded by the Leukemia Research Foundation in 2006.

Revenue and Other Support

<table>
<thead>
<tr>
<th></th>
<th>FYE 2020</th>
<th>FYE 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and grants</td>
<td>2,598,095</td>
<td>2,378,441</td>
</tr>
<tr>
<td>Other revenue</td>
<td>22,499</td>
<td>8,194</td>
</tr>
<tr>
<td>Total</td>
<td>2,620,594</td>
<td>2,386,635</td>
</tr>
</tbody>
</table>

Expense Allocation

<table>
<thead>
<tr>
<th>Expense Type</th>
<th>FYE 2020</th>
<th>FYE 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program service</td>
<td>1,954,968</td>
<td>1,839,495</td>
</tr>
<tr>
<td>research</td>
<td>1,349,295</td>
<td>1,227,593</td>
</tr>
<tr>
<td>patient financial assistance</td>
<td>266,021</td>
<td>169,710</td>
</tr>
<tr>
<td>patient education</td>
<td>339,652</td>
<td>392,192</td>
</tr>
<tr>
<td>Management</td>
<td>246,074</td>
<td>258,672</td>
</tr>
<tr>
<td>Fundraising</td>
<td>259,440</td>
<td>272,972</td>
</tr>
<tr>
<td>Total</td>
<td>2,460,482</td>
<td>2,371,139</td>
</tr>
</tbody>
</table>

change in net assets | 160,112 | 15,496 |
net assets (end of year) | 2,768,509 | 2,630,231 |

Expense Allocation

- Program Services: 10%
- Fundraising: 10.5%
- Management: 79.5%

Thank You

The Leukemia Research Foundation is grateful for all of its donors, sponsors and supporters, and acknowledges the generous contributions of these donors of $5,000 or more.

Abbvie, Inc.
Adaptive Biotechnologies Corporation
Estate of Fred Altergott
Rosemary Antosh
Astellas Pharma US, Inc.
Alison Bassetto
The Benevity Community Impact Fund
Jay A. and Maureen Bogg
Helen Brach Foundation
C-Quarters Marina, Inc.
Ceigele Corporation, Inc.
CFC, Inc.
CFG Community Bank
Lin and Adam Cheyer
Cole-Crone Family Foundation, Inc.
The Coleman Foundation, Inc.

Abe and Ida Cooper Foundation
Cressey Cares Charitable Fund of Community Fdn of Middle TN
Daichi Sankyo, Inc.
Marsha DeLuca
Harold Dreebin
George M. Eisenberg Foundation for Charities
Fred d’Escoho
First Midwest Bank
Estate of Ira Gertz
Gilead Sciences, Inc.
Gulf Coast Community Foundation
Healthcare Foundation of Highland Park
Craig Heberton IV & Marla S. Persky Trust
Incyte Corporation
Inspir - ClinicaHealth, Inc.
Lori S. Khanuk
Teddy Kim Foundation
Michael A. Kolodny
Lichtenheld Family Foundation
Gene A. Lynes
Ludwig Mannheimer Residuary Irrev Trust
Estate of Ethel Maybloom
Patricia Motejunas
Neff Family Trust
Nikoh Foundation
Novartis Pharmaceuticals Corp.
Outsource America, Inc.
Pfizer Inc.
Plexus Communications
Carolyn Pulliam
Renaissance Charitable Foundation
William R. Rich Foundation
Tracy Denmark Schwimmer
Senior Eye Associates, P.C.
Charles and M.R. Shapiro Foundation
Frances K. Showers
The Sunshine Foundation
Kenneth W. Thomas Memorial Trust
WLS-TV*
YourCause, LLC

* Indicates in-kind gift